^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    melphalan

    i
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1d
    Real MM: STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (clinicaltrials.gov)
    P4, N=450, Recruiting, University of Turin, Italy | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial primary completion date
    |
    lenalidomide • bortezomib • prednisone • dexamethasone • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    7d
    ElLen: Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients (clinicaltrials.gov)
    P3, N=824, Not yet recruiting, Intergroupe Francophone du Myelome
    New P3 trial
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    7d
    Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1, N=30, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    clonoSEQ
    |
    melphalan • CYT107
    9d
    CarMob: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Recruiting, Hackensack Meridian Health | Trial completion date: Dec 2024 --> Oct 2025 | Trial primary completion date: Dec 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • carfilzomib • melphalan • Neupogen (filgrastim) • dexamethasone injection
    9d
    AUTO-CAR-T: Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Xuzhou Medical University
    New P1 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • melphalan
    9d
    Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery (clinicaltrials.gov)
    P1, N=1, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Jul 2024
    Enrollment closed • Trial primary completion date
    |
    carboplatin • topotecan • melphalan
    13d
    Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=31, Completed, Cedars-Sinai Medical Center | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Feb 2025 | Trial primary completion date: Jun 2025 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    melphalan
    14d
    Pharmacokinetics of oral melphalan and its safety and efficacy in autologous hematopoietic stem cell transplantation for multiple myeloma (ChiCTR2500097863)
    P4, N=52, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    New P4 trial
    |
    melphalan
    16d
    Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (clinicaltrials.gov)
    P2, N=260, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Apr 2025
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • etoposide IV • sirolimus • melphalan • fludarabine IV • busulfan • cyclosporine
    16d
    Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas (clinicaltrials.gov)
    P1/2, N=20, Suspended, Insel Gruppe AG, University Hospital Bern | Trial completion date: Nov 2024 --> Apr 2025
    Trial completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    cytarabine • Adcetris (brentuximab vedotin) • melphalan
    16d
    UKALL14: Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=0, Completed, University College, London | Active, not recruiting --> Completed | N=1033 --> 0 | Trial completion date: Dec 2025 --> Feb 2025
    Trial completion • Enrollment change • Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    Rituxan (rituximab) • imatinib • cytarabine • cyclophosphamide • etoposide IV • vincristine • daunorubicin • melphalan • Oncaspar liquid (pegaspargase) • fludarabine IV • nelarabine • mercaptopurine • Kepivance (palifermin)
    19d
    SCANDIUM II: Isolated Hepatic Perfusion in Combination with Ipilimumab and Nivolumab in Patients with Uveal Melanoma Metastases (clinicaltrials.gov)
    P1, N=18, Completed, Vastra Gotaland Region | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • melphalan
    19d
    MOCCCA: Chemotherapy and G-CSF for Mobilization (clinicaltrials.gov)
    P2, N=137, Completed, Insel Gruppe AG, University Hospital Bern | Active, not recruiting --> Completed
    Trial completion
    |
    gemcitabine • vinorelbine tartrate • melphalan
    20d
    Changes of Cytokines in Aqueous Humor of Retinoblastoma with Intravitreal Melphalan. (PubMed, Retina)
    The results revealed a notable increase in cytokine levels subsequent to IVM interventions. Elevated cytokine concentrations in the eyes of RB patients post-IVM may be associated with ocular toxicities.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL11 (C-C Motif Chemokine Ligand 11) • IL17A (Interleukin 17A) • IL15 (Interleukin 15) • IL5 (Interleukin 5)
    |
    melphalan
    20d
    PRESERVE I: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Ossium Health, Inc. | Trial completion date: Aug 2025 --> Nov 2027 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    21d
    Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024
    Trial completion • Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Chr del(17p)
    |
    bortezomib • sirolimus • melphalan • fludarabine IV
    23d
    Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jan 2026
    Trial completion date
    |
    sirolimus • melphalan • fludarabine IV • itacitinib (INCB039110)
    27d
    Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor (clinicaltrials.gov)
    P1, N=25, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    topotecan • melphalan • busulfan • Neupogen (filgrastim)
    27d
    Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=29, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Dec 2025 --> Mar 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    melphalan • fludarabine IV • busulfan • ATA520
    27d
    Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=25, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024
    Trial completion • Trial completion date
    |
    CD34 (CD34 molecule)
    |
    cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab)
    27d
    Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • CD34 (CD34 molecule)
    |
    cytarabine • etoposide IV • etoposide oral • carmustine • melphalan • Simulect (basiliximab)
    29d
    Discordant lymphoma characterized by the coexistence of diffuse large B-cell lymphoma in the brain and mantle cell lymphoma in the colon, rectum, and bone marrow. (PubMed, Brain Tumor Pathol)
    After five cycles of R-MPV (rituximab, methotrexate, procarbazine, vincristine) therapy and three cycles of R-ESHAP (rituximab, etoposide, cytarabine, cisplatin, methylprednisolone) therapy, the patient received autologous hematopoietic stem cell transplantation using R-MEAM (rituximab, ranimustine, etoposide, cytarabine, melphalan) regimen after bridging therapy with ibrutinib. He did not relapse within 3 years of transplantation. To the best of our knowledge, this is the first case report of DLBCL and MCL coexistence.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    cisplatin • Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • etoposide IV • methotrexate • vincristine • melphalan • Matulane (procarbazine hydrochloride) • Cymerin (ranimustine)
    29d
    Regulating the expression of matrix metalloproteinases to inhibit ovarian carcinoma using isoquinoline alkaloid from Allium ascalonicum. (PubMed, Sci Rep)
    Docking results, revealed three potential phyto-nutraceuticals, of which, 1-[[3,5-bis(phenylmethoxy)phenyl]methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinoline, an isoquinoline alkaloid was considered the best, since it exhibits significant binding affinity when compared to that of the standard drug, Melphalan...Furthermore, simulation studies of finest interaction pose of the target MMPs with the best phyto-nutraceutical, revealed stable interactions and occurrence of conformational changes. The results, also suggested that, the best phyto-nutraceutical of Allium ascalonicum is a novel isoquinoline alkaloid, with favorable bioavailability scores that interact with target MMPs to control the progression and metastasis of ovarian cancer, proposing the prospect of formulating it into sustainable medications for treating metastasized Ovarian Cancer.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • MMP14 (Matrix Metallopeptidase 14)
    |
    melphalan
    29d
    A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    melphalan • busulfan
    30d
    GALAXY33: Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, German Cancer Research Center | Trial completion date: Feb 2025 --> Jan 2030 | Trial primary completion date: Feb 2025 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    CD33 (CD33 Molecule)
    |
    Mylotarg (gemtuzumab ozogamicin) • melphalan
    1m
    Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. (PubMed, Blood Adv)
    Combining these variables, we constructed a hierarchical model that stratified patients into low-, intermediate, and high-risk categories with 1-year RFS of 81.3%, 31.3% and 6.7%, respectively (P<0.001). In conclusion, a subset of MN harboring TP53mut who have low blasts pre-alloHCT and received melphalan-based conditioning derived long-term benefit from alloHCT.
    Journal
    |
    TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TP53 mutation • ASXL1 mutation • TET2 mutation
    |
    melphalan
    1m
    Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov)
    P2, N=153, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • humanised dinutuximab (Hu14.18K322A)
    1m
    Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Feb 2025 --> Jun 2025
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    melphalan • fludarabine IV
    1m
    Lenalidomide, Bortezomib and Dexamethasone Induction Therapy with Either Intravenous or Subcutaneous Isatuximab in Patients with Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=514, Active, not recruiting, University of Heidelberg Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • isatuximab subcutaneous (SAR650984 SC)
    1m
    UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (clinicaltrials.gov)
    P3, N=177, Active, not recruiting, University of Arkansas | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • thalidomide • melphalan
    1m
    Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    cisplatin • paclitaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • melphalan • mesna • Neupogen (filgrastim)
    1m
    Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Oct 2025
    Trial completion date
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    sirolimus • clofarabine • melphalan
    2ms
    NCI-2020-01626: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=60, Recruiting, Fred Hutchinson Cancer Center | N=45 --> 60
    Enrollment change
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    2ms
    Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma (clinicaltrials.gov)
    P=N/A, N=18, Recruiting, Eye & ENT Hospital of Fudan University | Trial primary completion date: May 2025 --> May 2028
    Trial primary completion date
    |
    melphalan
    2ms
    Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2028 --> Oct 2025 | Trial primary completion date: Nov 2028 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    melphalan • fludarabine IV
    2ms
    Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies (clinicaltrials.gov)
    P2, N=61, Recruiting, Shanghai Jiao Tong University School of Medicine | Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    melphalan • fludarabine IV • busulfan
    2ms
    Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=75, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Apr 2025
    Trial completion date
    |
    sirolimus • melphalan • fludarabine IV
    2ms
    Structural basis of anticancer drug recognition and amino acid transport by LAT1. (PubMed, Nat Commun)
    JPH203 (also known as nanvuranlat or KYT-0353), an anticancer drug in clinical trials, traps LAT1 in an outward-facing state with a U-shaped conformer, with its amino-phenylbenzoxazol moiety pushing against transmembrane helix 3 (TM3) and bending TM10. Physiological substrates like ʟ-Phe lack such effects, whereas melphalan poses steric hindrance, explaining its inhibitory activity. The "classical" system L inhibitor BCH induces an occluded state critical for transport, confirming its substrate-like behavior. These findings provide a structural basis for substrate recognition and inhibition of LAT1, guiding future drug design.
    Journal
    |
    SLC7A5 (Solute Carrier Family 7 Member 5)
    |
    melphalan • nanvuranlat (JPH203)
    2ms
    Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    melphalan
    2ms
    DEFENCE: Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients (clinicaltrials.gov)
    P2, N=8, Completed, Arbeitsgemeinschaft medikamentoese Tumortherapie | Active, not recruiting --> Completed
    Trial completion
    |
    Prolia (denosumab) • melphalan
    2ms
    FRE: Fluoroquinolone Resistance Prevalence Study (clinicaltrials.gov)
    P=N/A, N=105, Active, not recruiting, Hackensack Meridian Health | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD34 (CD34 molecule)
    |
    melphalan
    2ms
    Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov)
    P3, N=200, Enrolling by invitation, Wuhan Union Hospital, China | Recruiting --> Enrolling by invitation | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jan 2025 --> Dec 2025
    Enrollment status • Trial completion date • Trial primary completion date
    |
    melphalan • fludarabine IV • busulfan